Results 101 to 110 of about 138,725 (257)

Tofacitinib for Pityriasis Rubra Pilaris: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Hongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Tan H, Zhang B, Kang X, Wang L, Qiu X, Hu X   +5 more
doaj  

Oncostatin M-driven macrophage-fibroblast circuits as a drug target in autoimmune arthritis

Inflammation and Regeneration
Background Recent single-cell RNA sequencing (scRNA-seq) analysis revealed the functional heterogeneity and pathogenic cell subsets in immune cells, synovial fibroblasts and bone cells in rheumatoid arthritis (RA).
Nam Cong-Nhat Huynh, Rui Ling, Masatsugu Komagamine, Tianshu Shi, Masayuki Tsukasaki, Kotaro Matsuda, Kazuo Okamoto, Tatsuo Asano, Ryunosuke Muro, Warunee Pluemsakunthai, George Kollias, Yuko Kaneko, Tsutomu Takeuchi, Sakae Tanaka, Noriko Komatsu, Hiroshi Takayanagi   +15 more
doaj   +1 more source

Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study

, 2023
Lieke E.J.M. Scheepers, Yifei Yang, Yi Lung Chen, Graeme Jones   +3 more
openalex   +1 more source

AB0397 NO CLINICALLY RELEVANT CHANGES IN COAGULATION ACTIVATION BETWEEN PATIENTS INITIATING TNF-BLOCKERS VERSUS JAK-INHIBITORS [PDF]

, 2023
R. Hansildaar, Reinder Raadsen, Maaike Heslinga, Michael T. Nurmohamed   +3 more
openalex   +1 more source

Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant‐induced arthritis model: a translational study [PDF]

, 2012
Cristina Balagué, Mercè Pont, Neus Prats, Núria Godessart   +3 more
openalex   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment

Frontiers in Medicine
IntroductionAchieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments. Our study examines factors influencing Janus kinase (JAK)
Cristina Martinez-Molina, Cristina Martinez-Molina, Silvia Vidal, Silvia Vidal, Cesar Diaz-Torne, Cesar Diaz-Torne, Cesar Diaz-Torne, Hye S. Park, Hye S. Park, Hye S. Park, Hèctor Corominas, Hèctor Corominas, Hèctor Corominas   +12 more
doaj   +1 more source

SAR Studies on the Inhibitors for the Treatment of Inflammatory Diseases [PDF]

, 2016
School of Molecular Sciences(Chemistry)Inflammation is defensive host response that occurs from infection and injury and the inflammatory process is the pivotal physiological response of our body and essential part of the human physiology.
Kim, Min-Jeong
core  

AB0307 JAK INHIBITORS DO NOT WORSEN RA-ILD; COMPARISON OF CHANGES IN CT IMAGES AND KL-6/SP-D LEVELS BETWEEN PERIODS WITH BIOLOGICS AND WITH JAK INHIBITORS IN THE SAME INDIVIDUALS [PDF]

, 2023
A. Tanaka, Ryoko Koike, Ryosuke Sato, A Kikuchi, Shuhei Komatsu, Anna Hasegawa, T. Hiyama, Emi Fukasawa, T. Miyao, Satoko Arai, Takayoshi Owada, Reika Maezawa, Masafumi Arima, Kazuhiro Kurasawa   +13 more
openalex   +1 more source

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022

Heliyon
Background: The efficacy and safety of Janus kinase (JAK) inhibitors as novel therapeutic agents for psoriasis (PSO) and psoriatic arthritis (PsA) have not yet been systematically evaluated.
Jiao Wang, Tian Ma, Xiaoying Sun, Liu Liu, Seokgyeong Hong, Huijung Cha, Miao Zhang, Jiale Chen, Naixuan Lin, Bin Li, Xin Li   +10 more
doaj   +1 more source

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [PDF]

, 2018
William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo, Stefan N. Constantinescu   +5 more
openalex   +1 more source